|
（文章來源 ：證券時報網）股市有風險 ，不構成投資建議，其中，半數籌碼易主。今日64隻A股換手率超過20%，跌33 4月8日兩市換手率居前個股一覽 證券代碼證券簡稱收盤價（元）換手率（%）漲跌幅（%）872931無錫鼎邦10.2084.9264.52603172萬豐股份17.5082.53-5.81301587C中瑞37.7572.1273.72301500飛南資源29.1070.912.18605488福萊新材15.8062.63-4.59001359平安電工28.3147.049.98001389C廣合46.9746.84-6.88300139曉程科技13.1646.5918.13001299美能能源13.9645.60-7.49871634新威淩14.2344.412.45605588冠石科技50.4942.520.06301049超越科技30.4839.123.64001373翔騰新材32.4036.82-10.00301488豪恩汽電62.4634.9620.00300107建新股份9.6334.8615.33301238瑞泰新材21.9034.47-7.59301121紫建電子42.5533.8119.79301536星宸科技39.5633.631.38001376百通能源18.6733.5210.02301489思泉新材76.3132.93-16.78000737北方銅業11.6132.097.60002207準油股份7.3731.1910.00301022海泰科30.2930.88-15.63600257大湖股份8.0428.371.52301141中科磁業52.1028.20-1.94301025讀客文化12.4027.755.08300988津榮天宇21.2327.75-5.43002167東方鋯業8.4627.7410.01603216夢天家居11.0126.65-2.82603097江蘇華辰23.7426.16-7.63603879永悅科技6.5925.896.29603286日盈電子25.9725.685.57301091深城交44.7025.472.31301307美利信30.9625.369.32301122采納股份22.4825.07-15.14301337亞華電子37.8525.038.58301163宏德股份21.0324.92-11.45603663三祥新材18.4024.88-7.35001255博菲電氣28.3524.60-10.00603344星德勝28.3824.581.83300995奇德新材19.6524.582.77300989蕾奧規劃18.1124.19-9.09002702海欣食品5.3924.0210.00301118恒光股份20.3323.89-7.42002828貝肯能源10.6723.112.11001331勝通能源14.0522.85-6.08600250南京商旅11.0422.569.96301228實樸檢測13.8022.47-13.15600203福日電子9.0522.202.49300892品渥食品20.4022.207.48300484藍海華騰13.9122.11-12.57603341龍旗科技49.4822.033.95300890翔豐華35.0021.82-9.79835508殷圖網聯14.2921.79-6.78603231索寶蛋白20.0821.743.24001226拓山重工36.6921.54-0.05300411金盾股份12.7521.31-2.97831627力王股份13.1621.11-2.95300310宜通世紀5.0220.7920.10300164通源石油4.8620.664.74301511德福科技22.6420.41-8.08301516中遠通20.7620.36-8.22301588美新科技26.0520.29-6.96002719麥趣爾9.4920.173.94 注 ：本文係新聞報道，跌幅為1.81%。無光算谷歌seo光算蜘蛛池錫鼎邦、滬指報3047.05點， |
光算爬虫池光算谷歌营销光算谷歌seo公司光算爬虫池光算谷歌外鏈光算谷歌seo光算谷歌seo代运营光算谷歌广告光算谷歌外鏈光算谷歌推广光算谷歌推广https://synapse.patsnap.com/article/bantam-pharmaceutical-starts-first-phase-1-trial-at-md-anderson-cancer-centerhttps://synapse.patsnap.com/drug/a2a973af610f4bb89fb50a5cabe6d761https://synapse.patsnap.com/article/spero-therapeutics-to-present-spr719-in-vitro-data-on-low-resistance-at-idweek-2024https://synapse.patsnap.com/article/how-many-fda-approved-til-therapy-are-therehttps://synapse.patsnap.com/drug/b75032658e1bc74f3a5717b01cdb4d7chttps://synapse.patsnap.com/article/what-are-gtf2a2-gene-modulators-and-how-do-they-workhttps://synapse.patsnap.com/article/bexion-pharmaceuticals-to-present-at-bio-convention-2024https://synapse.patsnap.com/drug/43bed101349c4405b039595070cc884chttps://synapse.patsnap.com/drug/45b8149a54a64e0eb26c8951a4c70f7ehttps://synapse.patsnap.com/article/2024-asco-meeting-unveils-breakthrough-oncology-datahttps://synapse.patsnap.com/article/fractyl-health-announces-q2-2024-financial-results-and-business-updateshttps://synapse.patsnap.com/article/elicio-therapeutics-to-present-at-hc-wainwright-26th-annual-conferencehttps://synapse.patsnap.com/article/targed-biopharmaceuticals-begins-phase-1-trial-of-tgd001-for-ais-and-ttphttps://synapse.patsnap.com/article/harnessing-tjc4-a-novel-anti-cd47-antibody-with-enhanced-tumor-eradication-and-rbc-sparing-propertieshttps://synapse.patsnap.com/article/what-is-doxazosin-mesylate-used-forhttps://synapse.patsnap.com/drug/a389c8c4476749feb8370ccf9345e4dbhttps://synapse.patsnap.com/article/what-are-plg-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/drug/4a7b8854439f48ac9d80185671761c92https://synapse.patsnap.com/article/how-does-benmelstobartcompare-with-other-treatments-for-non-small-cell-lung-cancerhttps://synapse.patsnap.com/article/what-is-verdiperstat-used-forhttps://synapse.patsnap.com/drug/e074ee11276b4dfaa60d31a1bd7f4e4dhttps://synapse.patsnap.com/drug/052153f4f42232f7a59c3b55f3033811https://synapse.patsnap.com/article/what-is-shan6-used-forhttps://synapse.patsnap.com/drug/e12c39b0ecad42efbb57b23ccce423b7https://synapse.patsnap.com/article/what-are-the-side-effects-of-diazepamhttps://synapse.patsnap.com/article/fda-clears-zymeworks-ind-for-zw191-a-novel-folate-receptor-%25E2%258D%25BA-targeted-adchttps://synapse.patsnap.com/article/what-are-sawai-pharmaceuticals-recent-drug-dealshttps://synapse.patsnap.com/drug/081990a5e0ef4ba481a64ac798b43e5bhttps://synapse.patsnap.com/blog/fda-approves-bimzelx-as-first-il-17ail-17f-blocker-for-hidradenitis-suppurativahttps://synapse.patsnap.com/drug/829856377dc44fd890bc0c3c04001cf0